CD47 and triple-A syndrome: By targeting upstream immune dysregulation rather than downstream proteolytic pathways, modulation of the TSP1–CD47 axis may provide the first disease-modifying pharmacological therapy for AAA, complementing or delaying the need for surgical repair [18,19].